β-cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1α and glucokinase mutations

Ewan R. Pearson, Gilberto Velho, Penny Clark, Amanda Stride, Maggie Shepherd, Timothy M. Frayling, Michael P. Bulman, Sian Ellard, Phillipe Froguel, Andrew T. Hattersley (Lead / Corresponding author)

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Mutations in the β-cell genes encoding the glycolytic enzyme glucokinase (GCK) and the transcription factor hepatocyte nuclear factor (HNF)-1α are the most common causes of maturity-onset diabetes of the young (MODY). Studying patients with mutations in these genes gives insights into the functions of these two critical β-cell genes in humans. We studied 178 U.K. and French MODY family members, including 45 GCK mutation carriers and 40 HNF-1α mutation carriers. Homeostasis model assessment of fasting insulin and glucose showed reduced β-cell function in both GCK (48% controls, P < 0.0001) and HNF-1α (42% controls, P < 0.0001). Insulin sensitivity was similar to that of control subjects in the GCK subjects (93% controls, P = 0.78) but increased in the HNF-1α subjects (134.5% controls, P = 0.005). The GCK patients showed a similar phenotype between and within families with mild lifelong fasting hyperglycemia (fasting plasma glucose [FPG] 5.5-9.2 mmol/l, interquartile [IQ] range 6.6-7.4), which declined slightly with age (0.017 mmol/l per year) and rarely required pharmacological treatment (17% oral hypoglycemic agents, 4% insulin). HNF-1α patients showed far greater variation in fasting glucose both between and within families (FPG 4.1-18.5 mmol/l, IQ range 5.45-10.4), with a marked deterioration with age (0.06 mmol/l per year), and 59% of patients required treatment with tablets or insulin. Proinsulin-to-insulin ratios are increased in HNF-1α subjects (29.5%) but not in GCK (18.5%) subjects. In an oral glucose tolerance test, the 0- to 120-min glucose increment was small in GCK patients (2.4 ± 1.8 mmol/l) but large in HNF-1α patients (8.5 ± 3.0 mmol/l, P < 0.0001). This comparison shows that the clear clinical differences in these two genetic subgroups of diabetes reflect the quantitative and qualitative differences in β-cell dysfunction. The defect in GCK is a stable defect of glucose sensing, whereas the HNF-1α mutation causes a progressive defect that alters β-cell insulin secretion directly rather than the sensing of glucose.

Original languageEnglish
Pages (from-to)S101-S107
Number of pages7
JournalDiabetes
Volume50
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 22 Feb 2001

Fingerprint Dive into the research topics of 'β-cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1α and glucokinase mutations'. Together they form a unique fingerprint.

  • Cite this

    Pearson, E. R., Velho, G., Clark, P., Stride, A., Shepherd, M., Frayling, T. M., Bulman, M. P., Ellard, S., Froguel, P., & Hattersley, A. T. (2001). β-cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1α and glucokinase mutations. Diabetes, 50(SUPPL. 1), S101-S107. https://doi.org/10.2337/diabetes.50.2007.S101